Introduction
Most drug development programs are built around an adult population first, and pediatric use gets addressed later, sometimes much later. But regulators in the US and EU have spent the last two decades tightening the rules around when and how sponsors have to study a product in children, and that shift has created steady, specialized regulatory affairs work that does not get nearly as much attention as flashier hiring niches like cell and gene therapy or AI-enabled devices. If you want to understand where a reliable, less-crowded slice of regulatory demand sits right now, pediatric development is worth a closer look.
The two frameworks driving the work
In the United States, the Pediatric Research Equity Act (PREA) generally requires sponsors of new drugs and biologics to assess safety and effectiveness in relevant pediatric populations, unless the product qualifies for a waiver or deferral. That assessment has to be planned early: sponsors submit an initial Pediatric Study Plan and negotiate it with FDA, well before the adult program has finished generating the data that will eventually support pediatric extrapolation or dedicated pediatric trials. On the incentive side, the Best Pharmaceuticals for Children Act (BPCA) offers additional exclusivity to sponsors who voluntarily study a product in children, even when PREA does not strictly require it, which creates commercial reasons to pursue pediatric work beyond the compliance floor.
In the European Union, the parallel mechanism is the Paediatric Investigation Plan (PIP), required under the EU's pediatric regulation for most new medicines. A PIP has to be agreed with EMA's Paediatric Committee (PDCO) early in development, describing the studies, formulations, and timelines a sponsor will pursue across pediatric age subsets, again with the possibility of waivers for products unlikely to be used in children or deferrals when adult data needs to come first. Getting a PIP wrong, or leaving it too late, can hold up a marketing authorization application entirely, which is a much sharper consequence than many sponsors expect the first time they run into it.
Together, these two frameworks mean that a meaningful share of drug and biologic development programs need a formal pediatric regulatory strategy years before any child is enrolled in a study, and that strategy has to be revisited and often renegotiated as the adult program evolves.
Why this creates a distinct hiring niche
Pediatric regulatory work does not fit neatly inside a generalist role, for a few reasons. The negotiation processes themselves are procedurally distinct from the core IND or marketing authorization pathway, with their own submission formats, their own review bodies, and their own timelines that have to be tracked in parallel with the main development plan. The scientific issues are also genuinely different: extrapolating adult efficacy data to pediatric populations, designing age-appropriate formulations, and running trials in small, vulnerable populations all require judgment calls that a regulatory professional focused purely on adult indications may not have built up.
On top of that, waivers and deferrals are negotiated positions, not automatic outcomes, and a sponsor's ability to argue convincingly for one depends on regulatory professionals who understand precedent across therapeutic areas and can build a scientifically defensible rationale rather than simply asserting that pediatric studies are impractical.
Because relatively few regulatory professionals build deep pediatric-specific experience, companies with active development pipelines — particularly in therapeutic areas where pediatric prevalence is meaningful, such as oncology, rare disease, infectious disease, and metabolic conditions — tend to compete for a fairly small pool of people who genuinely know this space well. That scarcity is what makes it worth calling out as its own hiring niche rather than just a subset of general regulatory strategy work.
What the work actually looks like
People doing this work spend a lot of time on documents most regulatory professionals rarely touch: Pediatric Study Plans and their EU counterpart PIPs, waiver and deferral requests with supporting scientific rationale, and correspondence with FDA's pediatric review staff or EMA's PDCO. They coordinate closely with clinical teams designing age-appropriate dosing and formulation studies, since a formulation that works for an adult population, such as a large tablet, often is not usable in a young child, which can itself become a regulatory and development challenge.
They also track a genuinely global patchwork, since pediatric requirements and incentive structures differ meaningfully between the US, EU, and other major markets, and a program running in multiple regions needs someone who can reconcile plans that were negotiated separately with different agencies and sometimes contain different age-subset definitions or study expectations.
Who is hiring for this
Pharmaceutical and biotechnology companies with pipelines in oncology, rare disease, and pediatric-relevant infectious or metabolic conditions are the most consistent source of this work, particularly once a program reaches the stage where an initial pediatric plan has to be filed. Regulatory consultancies that support multiple sponsor companies also carry a steady flow of pediatric strategy work, since it is exactly the kind of specialized, intermittent need that smaller companies without in-house pediatric expertise are willing to pay for on a project basis rather than building the capability internally.
Because pediatric regulatory work spans development stages rather than sitting entirely at the start or end of a program, people who build this expertise often stay involved with a product for years, which is a different rhythm than roles tied to a single submission event.
Where sponsors run into trouble
The most common misstep is treating the pediatric plan as an administrative filing to be dealt with later rather than a scientific and strategic decision with real consequences for timing. Because a Pediatric Study Plan or PIP has to be agreed early, often before a company has fully committed to its adult clinical strategy, sponsors that delay engaging with it can find themselves negotiating pediatric commitments against a moving target, redrafting the plan repeatedly as the adult program's endpoints or population definitions shift. Each redraft consumes agency review cycles and internal bandwidth that a more proactive approach would have avoided.
A second common problem is underestimating how much the formulation and dosing questions differ by age subset. A plan that treats "pediatric" as a single category rather than breaking it into the age bands agencies actually expect — neonates, infants, children, and adolescents look nothing alike from a dosing or formulation standpoint — tends to draw repeated agency questions and can stall a review. Sponsors that bring in pediatric regulatory expertise early enough to get the age-subset strategy right the first time avoid a meaningful amount of back-and-forth later.
A third issue, more organizational than scientific, is failing to keep the pediatric plan synchronized with the rest of the development program as it evolves. A PIP or Pediatric Study Plan is not a one-time filing; it gets revisited as new data comes in, and a regulatory function that treats it as "filed and done" rather than a living document that needs periodic reassessment can be caught off guard when a marketing authorization application is held up by an out-of-date pediatric commitment.
What this means for compensation and career leverage
Specialization does not automatically translate into a title bump, but it does tend to translate into leverage. Regulatory professionals with a track record of successfully negotiated waivers, deferrals, or PIPs bring a scarce, demonstrable skill into salary and role negotiations, and it is the kind of experience that reads clearly on a resume rather than needing much explanation to a hiring manager who already knows the space. It also tends to travel well between employers, since the procedural skill of negotiating with FDA's pediatric review staff or EMA's PDCO applies almost as directly at one sponsor company as another, which is not true of every regulatory specialization.
It is worth being honest about the limits of this leverage, too. Pediatric regulatory work is a genuine niche, not a mass-market specialization, so the number of roles that call for it explicitly at any given time is modest. The advantage shows up less in a large volume of open pediatric-specific job postings and more in being the clear, differentiated candidate when a company with an active pediatric-inclusive pipeline does need to hire.
Building this expertise
There is no dedicated academic credential that reliably signals pediatric regulatory expertise, so most people build it on the job, typically after a few years in a general regulatory affairs role, by volunteering for programs that have an active pediatric component and staying close to the sponsor's interactions with FDA's pediatric review staff or EMA's PDCO. Reading published pediatric study plans and PIP decisions, where available, is a practical way to build pattern recognition for how waivers and deferrals get argued and granted. Professional organizations such as RAPS occasionally offer training modules specifically on pediatric regulatory requirements, which can accelerate the learning curve for someone trying to build this specialization deliberately rather than by accident.
For people already in regulatory affairs looking for a way to differentiate themselves without switching therapeutic areas entirely, deliberately seeking out pediatric-inclusive programs is one of the more accessible ways to build a specialty that is genuinely in short supply.
Conclusion
Pediatric regulatory work will never generate the hiring headlines that novel modalities or AI-enabled devices do, but it is a steady, procedurally distinct niche that a relatively small number of regulatory professionals understand well. For sponsors, that scarcity translates into real hiring difficulty when a program approaches its Pediatric Study Plan or PIP deadline. For regulatory professionals, it is a specialization worth considering if you want expertise that stays relevant across many therapeutic areas and keeps you close to a product across a longer stretch of its development lifecycle than most regulatory roles allow.